High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

PASZEKOVÁ Helena KRYUKOV Fedor KUBICZKOVÁ Lenka HÁJEK Roman ŠEVČÍKOVÁ Sabina

Year of publication 2014
Type Article in Periodical
Magazine / Source Clinical lymphoma, myeloma & leukemia
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1016/j.clml.2013.09.004
Field Oncology and hematology
Keywords Cytogenetics; GEP; High-risk disease; MGUS; Multiple myeloma; Prognosis
Description Multiple myeloma (MM) is a clonal plasma cell malignancy. Although MM is still not completely curable, it can be maintained at the level of a long-term chronic condition. Irrespective of the treatment strategy, relapse is still a major problem for most patients. Approximately 10% to 15% of all MM patients relapse early and have poor prognosis and outcome. Currently, there are many ways of identifying these high-risk patients using cytogenetics or molecular biology. Despite these various approaches to definition of high risk patients, a clear definition of high-risk MM has not been widely accepted. In this review, we discuss and compare various approaches, and their strengths and weaknesses in early identification of high-risk MM patients.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.